B. Krayim

Overcoming CEP85L-ROS1, MKRN1-BRAF and MET amplification as rare, acquired resistance mutations to Osimertinib

L. Roisman, N. Peled, W. Kian, 2023, Frontiers in Oncology.

An Unusual Presentation of HCC in a Patient with No Underlying Liver Disease: A Case Study

G. Sebbag, W. Kian, W. Shalata, 2022, Case Reports in Oncology.

Real-world efficacy and safety of mobocertinib in EGFR exon 20 insertion-mutated lung cancer

L. Roisman, N. Peled, P. Christopoulos, 2022, Frontiers in Oncology.

Neoadjuvant osimertinib followed by sequential definitive radiotherapy and/or surgery in stage III EGFR-mutant NSCLC: An open-label, single-arm, phase II study.

P. Blumenfeld, S. Tsuriel, H. Nechushtan, 2023, International journal of radiation oncology, biology, physics.